{
    "clinical_study": {
        "@rank": "57084", 
        "arm_group": [
            {
                "arm_group_label": "DRM02", 
                "arm_group_type": "Experimental", 
                "description": "DRM02 Topical Gel, 0.25%"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "DRM02 Topical Gel, Vehicle"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether DRM02 is safe and effective in the\n      treatment of plaque psoriasis when applied twice daily for 6 weeks."
        }, 
        "brief_title": "A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Psoriasis", 
        "condition_browse": {
            "mesh_term": "Psoriasis"
        }, 
        "detailed_description": {
            "textblock": "This is a double-blind, randomized, within-subject control, study enrolling 20 subjects with\n      plaque psoriasis and designed to assess the safety, tolerability, and preliminary efficacy\n      of DRM02.\n\n      Safety will be assessed during the study, through adverse events, local skin responses,\n      urinalysis, serum chemistry and hematology laboratory testing, physical examination and\n      vital signs.\n\n      Preliminary efficacy will be assessed through the Physician's Lesion Assessment (PLA) and\n      the Severity of Psoriasis Area Severity Index (PASI) from only the two plaques identified at\n      the baseline visit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18 to 70 years of age.\n\n          -  Plaque-type psoriasis with two lesions of similar size and have an identical score of\n             at least 6 but no more than 8 on the sum of the individual components of the Severity\n             of Psoriasis Area Severity Index (PASI) at the Target Lesion scale.\n\n          -  Male or non-pregnant, non-lactating females.\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Subjects who have extensive, and/or 'inverse', and/or exfoliative psoriasis.\n\n          -  Subjects who have taken any systemic treatment for psoriasis within the 4 weeks prior\n             to baseline.\n\n          -  Prior or concomitant use of topical treatments for psoriasis to within 10 cm of the\n             target lesion within the 4 weeks prior to baseline.\n\n          -  Use of Enbrel within the 4 weeks prior to baseline.\n\n          -  Psoralen & ultraviolet A therapy (PUVA) or the use of ultraviolet B (UVB) therapy\n             and/or excessive or prolonged exposure to ultraviolet light within the 4 weeks prior\n             to baseline.\n\n          -  Use of Humira or Remicade within the 3 months prior to baseline.\n\n          -  Use of Stelara within the 6 months prior to baseline.\n\n          -  Subjects who have taken oral retinoids for psoriasis within the 6 months prior to\n             baseline.\n\n          -  Subjects who have poor skin condition within 5 cm of the target lesion.\n\n          -  Subjects who are current drug or alcohol abusers; have a history of immunodeficiency\n             disease or are a poor medical risk because of other systemic diseases or active\n             uncontrolled infections.\n\n          -  Subjects with an unstable medical condition or a medical condition not adequately\n             controlled with standard medical therapy.\n\n          -  Subjects who are actively participating in an experimental therapy study or who have\n             received experimental therapy within 30 days\n\n          -  Subjects who have a clinically significant laboratory value at screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "23", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993433", 
            "org_study_id": "DRM02-PSO02"
        }, 
        "intervention": [
            {
                "arm_group_label": "DRM02", 
                "intervention_name": "DRM02", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Drummondville", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J2B5L4"
                    }, 
                    "name": "Clinique M\u00e9dicale Dr Isabelle Delorme"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2K 4L5"
                    }, 
                    "name": "Innovaderm Research, Inc"
                }
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Plaque Psoriasis", 
        "other_outcome": {
            "measure": "Severity of Target Lesion PASI scores", 
            "safety_issue": "No", 
            "time_frame": "Week 6"
        }, 
        "overall_official": {
            "affiliation": "Dermira, Inc.", 
            "last_name": "Beth Zib", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in Physician's Lesion Assessment", 
            "safety_issue": "No", 
            "time_frame": "Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993433"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Physician's Lesion Assessment", 
                "safety_issue": "No", 
                "time_frame": "From baseline to weeks 0, 1, 2, 3, 4 and 6"
            }, 
            {
                "measure": "PLA dichotomized into \"success\" and \"failure\"", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }
        ], 
        "source": "Dermira, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dermira, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}